On a call with investors this week, GW Pharmaceuticals revealed the price of Epidiolex, its newly-approved, marijuana-based drug for rare forms of epilepsy. Designed to treat two rare forms of childhood epilepsy using a marijuana compound called CBD, the drug is the first medication of its kind to get FDA approval. The person leading the company’s commercialization efforts in the US said the goal is to keep the price of the drug on par with other epilepsy medications. A marijuana-derived drug that recently became the first of its kind to win federal approval is not going to be cheap. Called Epidiolex, the drug is designed to treat two rare forms of childhood epilepsy using a cannabis compound called cannabidiol (or CBD).
On a call with investors this week, British-based GW Pharmaceuticals, who makes the drug, said it would cost roughly $32,500 per year. The medication does not contain THC, the well-known psychoactive component of marijuana responsible for the drug’s characteristic high. The drug maker behind the first FDA-approved medication derived from marijuana has revealed how much it’ll cost
thumbnail courtesy of businessinsider.com